Back to search results
NCT07450664

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

Enrolling by Invitation
Not specifiedAges 4+Observational
Soleno Therapeutics, Inc.
~200 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:VYKAT XR

At a glance

Recruiting sites
0 of 24 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess safety profile of patients with PWS treated with VYKAT XR.
Measured over Adverse events for each patient will be collected from the time of first dose on VYKAT XR until the last contact with the patient.

Conditions

Prader-Willi Syndrome

Explore related trials

Prader-Willi Syndrome

NCT07450664

Where you'd take part

This study runs at 24 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Neurocrine Clinical Site

    Phoenix, Arizonano site contact published

  • Neurocrine Clinical Site

    Los Angeles, Californiano site contact published

  • Neurocrine Clinical Site

    Sacramento, Californiano site contact published

  • Neurocrine Clinical Site

    Aurora, Coloradono site contact published

  • Neurocrine Clinical Site

    Atlanta, Georgiano site contact published

  • Neurocrine Clinical Site

    Chicago, Illinoisno site contact published

  • Neurocrine Clinical Site

    Indianapolis, Indianano site contact published

  • Neurocrine Clinical Site

    Boston, Massachusettsno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients currently receiving or initiating treatment with VYKAT XR, including patients who previously received DCCR or are transitioning from DCCR to VYKAT XR in the context of a prior DCCR clinical trial.
Patients and/or caregivers must provide written informed consent.

What this trial measures

  • Assess safety profile of patients with PWS treated with VYKAT XR.Adverse events for each patient will be collected from the time of first dose on VYKAT XR until the last contact with the patient.

    The safety profile will be based on adverse events, including nonserious adverse events, serious adverse events, and adverse events leading to discontinuation of VYKAT XR.